Valeant reports 77% first-quarter revenue increase

Valeant Pharmaceuticals reported revenue of $1.9 billion in the first quarter of 2014, an increase of 77% compared with last year’s earnings, according to a press release.The company also reported an increase in its developed market revenue of $1.4 billion, up 82% from the first quarter of 2013 as a result of promoted dermatology brands, consumer, neurology and other, and oral health businesses, as well as a 9% organic growth in Bausch + Lomb businesses, the release said.

Full Story →